Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX)

CUSIP: 22663K107

Q1 2023 13F Holders as of 31 Mar 2023

Type / Class
Equity / Common Stock, par value $0.001 per share (the "Shares")
Shares outstanding
94,401,153
Total 13F shares
55,062,782
Share change
+363,760
Total reported value
$884,310,368
Put/Call ratio
0.44%
Price per share
$16.06
Number of holders
127
Value change
+$2,280,401
Number of buys
78
Number of sells
41

Quarterly Holders Quick Answers

What is CUSIP 22663K107?
CUSIP 22663K107 identifies CRNX - Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX) as of Q1 2023

As of 31 Mar 2023, Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX) was held by 127 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 55,062,782 shares. The largest 10 holders included DRIEHAUS CAPITAL MANAGEMENT LLC, BlackRock Inc., ORBIMED ADVISORS LLC, WELLINGTON MANAGEMENT GROUP LLP, PERCEPTIVE ADVISORS LLC, BVF INC/IL, VANGUARD GROUP INC, Bain Capital Life Sciences Investors, LLC, STATE STREET CORP, and BRAIDWELL LP. This page lists 127 institutional shareholders reporting positions in this security for the Q1 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.